LL-37 (Cathelicidin Antimicrobial Peptide LL-37)
A human cathelicidin antimicrobial peptide with broad-spectrum activity against bacteria, viruses, and fungi. Also promotes wound healing and modulates innate immune response.
How it works
Disrupts microbial membranes, neutralizes endotoxins, recruits immune cells via chemotaxis, and promotes angiogenesis and re-epithelialization.
Key facts
- Molecular weight: 4493.33 Da
- Half-life: ~4-6 hours
- Bioavailability: Variable by route; topical and injectable
- Storage: Lyophilized: -20°C. Reconstituted: 2-8°C, use within 7 days.
Dosing overview
- Typical dose: 50-100 mcg
- Frequency: Daily
- Duration: 2-6 weeks
- Route: Topical or subcutaneous injection
Reported benefits
- Broad-spectrum antimicrobial
- Wound healing acceleration
- Biofilm disruption
- Immune system enhancement
Possible side effects
- Local irritation
- Redness at application site
- Mild inflammatory response
Research
- LL-37 in wound healing and infection control (2021): Enhanced wound closure rates and reduced bacterial colonization in chronic wound models.
- Cathelicidin peptides as innate immune modulators (2019): Demonstrated ability to shift macrophage polarization toward pro-healing M2 phenotype.
Compare LL-37
Community discussions about LL-37
- Anyone tried topical LL-37 on trail rash or road rash? - 4 comments
- BPC-157 and LL-37 for stubborn skin tears or scrapes? - 2 comments
- PE 22-28 TREK-1 blocker – what do we really know so far? - 7 comments
- Adding LL-37 for stubborn skin inflammation with BPC-157 - 6 comments
- Oral BPC-157 vs injectable for my knee tendonitis – what I noticed - 3 comments
- Ask the community about LL-37
Research and educational reference only. Not medical advice.